
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-a68b4900.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-0a3f24ce.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Pharmacology and Therapeutic Potential of Finerenone: A Novel Third-Generation Nonsteroidal Mineralocorticoid Receptor Antagonist - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="67D711E389B716831C11E300257DC069.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="cureus">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335729/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Cureus">
<meta name="citation_title" content="Pharmacology and Therapeutic Potential of Finerenone: A Novel Third-Generation Nonsteroidal Mineralocorticoid Receptor Antagonist">
<meta name="citation_author" content="Mahmoud M Ramadan">
<meta name="citation_author_institution" content="Department of Cardiology, Faculty of Medicine, Mansoura University, Mansoura, EGY">
<meta name="citation_author_institution" content="Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, ARE">
<meta name="citation_author" content="Shaha Alajmi">
<meta name="citation_author_institution" content="Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, ARE">
<meta name="citation_author" content="Jude Aldouseri">
<meta name="citation_author_institution" content="Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, ARE">
<meta name="citation_author" content="Manar Alajmi">
<meta name="citation_author_institution" content="Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, ARE">
<meta name="citation_author" content="Eva A Tello">
<meta name="citation_author_institution" content="Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, ARE">
<meta name="citation_author" content="Abdul-Majeed O Mahdi">
<meta name="citation_author_institution" content="Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, ARE">
<meta name="citation_author" content="Ahmad J Aladwani">
<meta name="citation_author_institution" content="Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, ARE">
<meta name="citation_author" content="Abdulrahman E Alayyaf">
<meta name="citation_author_institution" content="Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, ARE">
<meta name="citation_author" content="Ousama Mahdi">
<meta name="citation_author_institution" content="Department of Cardiology, University Hospital Sharjah, Sharjah, ARE">
<meta name="citation_author" content="Mohammed Elmahal">
<meta name="citation_author_institution" content="Department of Diabetes and Endocrinology, Khartoum North Teaching Hospital, Khartoum, SDN">
<meta name="citation_publication_date" content="2025 Jul 11">
<meta name="citation_volume" content="17">
<meta name="citation_issue" content="7">
<meta name="citation_firstpage" content="e87706">
<meta name="citation_doi" content="10.7759/cureus.87706">
<meta name="citation_pmid" content="40786373">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335729/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335729/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335729/pdf/cureus-0017-00000087706.pdf">
<meta name="description" content="Finerenone is a novel third-generation nonsteroidal mineralocorticoid receptor antagonist (MRA) that has demonstrated efficacy in treating chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF). Unlike traditional ...">
<meta name="og:title" content="Pharmacology and Therapeutic Potential of Finerenone: A Novel Third-Generation Nonsteroidal Mineralocorticoid Receptor Antagonist">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Finerenone is a novel third-generation nonsteroidal mineralocorticoid receptor antagonist (MRA) that has demonstrated efficacy in treating chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF). Unlike traditional ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335729/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/">
                    <img alt="
                                  NCBI home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12335729">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.7759/cureus.87706"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/cureus-0017-00000087706.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12335729%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12335729/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12335729/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335729/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-cureus.png" alt="Cureus logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Cureus" title="Link to Cureus" shape="default" href="http://www.cureus.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Cureus</button></div>. 2025 Jul 11;17(7):e87706. doi: <a href="https://doi.org/10.7759/cureus.87706" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.7759/cureus.87706</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Cureus%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cureus%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Cureus%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Cureus%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Pharmacology and Therapeutic Potential of Finerenone: A Novel Third-Generation Nonsteroidal Mineralocorticoid Receptor Antagonist</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ramadan%20MM%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Mahmoud M Ramadan</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Mahmoud M Ramadan</span></h3>
<div class="p">
<sup>1</sup>
Department of Cardiology, Faculty of Medicine, Mansoura University, Mansoura, EGY </div>
<div class="p">
<sup>2</sup>
Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, ARE </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ramadan%20MM%22%5BAuthor%5D" class="usa-link"><span class="name western">Mahmoud M Ramadan</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alajmi%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Shaha Alajmi</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Shaha Alajmi</span></h3>
<div class="p">
<sup>2</sup>
Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, ARE </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alajmi%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Shaha Alajmi</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Aldouseri%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Jude Aldouseri</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Jude Aldouseri</span></h3>
<div class="p">
<sup>2</sup>
Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, ARE </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Aldouseri%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jude Aldouseri</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alajmi%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Manar Alajmi</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Manar Alajmi</span></h3>
<div class="p">
<sup>2</sup>
Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, ARE </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alajmi%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Manar Alajmi</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tello%20EA%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Eva A Tello</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Eva A Tello</span></h3>
<div class="p">
<sup>2</sup>
Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, ARE </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tello%20EA%22%5BAuthor%5D" class="usa-link"><span class="name western">Eva A Tello</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mahdi%20AMO%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Abdul-Majeed O Mahdi</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Abdul-Majeed O Mahdi</span></h3>
<div class="p">
<sup>2</sup>
Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, ARE </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mahdi%20AMO%22%5BAuthor%5D" class="usa-link"><span class="name western">Abdul-Majeed O Mahdi</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Aladwani%20AJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Ahmad J Aladwani</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Ahmad J Aladwani</span></h3>
<div class="p">
<sup>2</sup>
Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, ARE </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Aladwani%20AJ%22%5BAuthor%5D" class="usa-link"><span class="name western">Ahmad J Aladwani</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alayyaf%20AE%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Abdulrahman E Alayyaf</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Abdulrahman E Alayyaf</span></h3>
<div class="p">
<sup>2</sup>
Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, ARE </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Alayyaf%20AE%22%5BAuthor%5D" class="usa-link"><span class="name western">Abdulrahman E Alayyaf</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mahdi%20O%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Ousama Mahdi</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Ousama Mahdi</span></h3>
<div class="p">
<sup>3</sup>
Department of Cardiology, University Hospital Sharjah, Sharjah, ARE </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mahdi%20O%22%5BAuthor%5D" class="usa-link"><span class="name western">Ousama Mahdi</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Elmahal%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Mohammed Elmahal</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Mohammed Elmahal</span></h3>
<div class="p">
<sup>4</sup>
Department of Diabetes and Endocrinology, Khartoum North Teaching Hospital, Khartoum, SDN </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Elmahal%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Mohammed Elmahal</span></a>
</div>
</div>
<sup>4</sup>
</div>
<div class="cg p">Editors: <span class="name western">Alexander Muacevic</span>, <span class="name western">John R Adler</span>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff-1">
<sup>1</sup>
Department of Cardiology, Faculty of Medicine, Mansoura University, Mansoura, EGY </div>
<div id="aff-2">
<sup>2</sup>
Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, ARE </div>
<div id="aff-3">
<sup>3</sup>
Department of Cardiology, University Hospital Sharjah, Sharjah, ARE </div>
<div id="aff-4">
<sup>4</sup>
Department of Diabetes and Endocrinology, Khartoum North Teaching Hospital, Khartoum, SDN </div>
<div class="author-notes p">
<div class="fn" id="cor1">
<sup>✉</sup><p class="display-inline">
Mahmoud M. Ramadan <span>amamod@gmail.com</span>
</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Accepted 2025 Jul 10; Collection date 2025 Jul.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>Copyright © 2025, Ramadan et al.</div>
<p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12335729  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40786373/" class="usa-link">40786373</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>Finerenone is a novel third-generation nonsteroidal mineralocorticoid receptor antagonist (MRA) that has demonstrated efficacy in treating chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF). Unlike traditional steroidal MRAs such as Spironolactone and Eplerenone, Finerenone offers high selectivity for MR, resulting in reduced off-target effects, including hyperkalemia and antiandrogenic side effects. It exerts renoprotective and cardioprotective effects through its anti-inflammatory and antifibrotic actions, making it a good therapeutic option for patients with CKD and HFrEF. The pharmacokinetic profile of Finerenone demonstrates rapid absorption, satisfactory oral bioavailability, and predictable systemic clearance, contributing to its efficacy and tolerability. Clinical trials, including advanced Phase III studies, have established Finerenone’s ability to delay CKD progression, reduce proteinuria, and improve cardiovascular (CV) outcomes (such as hospitalization for heart failure and CV death) in patients with diabetes mellitus and CKD. Compared to other MRAs, Finerenone demonstrates improved tolerability; however, clinically significant risks such as hyperkalemia necessitate proactive monitoring and protocol-driven management. Additionally, its unique molecular structure and mechanism of action make it a safer alternative for long-term use in diverse populations. While initial results are promising, further research is necessary to evaluate the long-term outcomes and explore its full therapeutic potential, including novel applications in high-risk patients and biomarker-driven treatments. These findings position finerenone as a valuable addition to current therapies for CKD and HFrEF, though broader adoption awaits real-world validation of its safety and cost-effectiveness.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> cardiovascular benefit, chronic kidney disease, chronic kidney disease (ckd), finerenone, heart failure, mineralocorticoid receptor antagonist, reduced ejection fraction, serum potassium level, third generation</p></section></section><section id="sec1"><h2 class="pmc_sec_title">Introduction and background</h2>
<p>Chronic kidney disease (CKD) and heart failure (HF) represent intertwined global health challenges, collectively affecting over 850 million people worldwide and driving substantial morbidity, mortality, and healthcare costs [<a href="#REF1" class="usa-link" aria-describedby="REF1">1</a>,<a href="#REF2" class="usa-link" aria-describedby="REF2">2</a>]. Central to their pathophysiology is the overactivation of the mineralocorticoid receptor (MR), a key mediator of aldosterone-induced sodium retention, potassium excretion, fibrosis, and inflammation [<a href="#REF3" class="usa-link" aria-describedby="REF3">3</a>,<a href="#REF4" class="usa-link" aria-describedby="REF4">4</a>]. Mineralocorticoid receptor antagonists (MRAs) counteract these effects, offering renal and cardiovascular (CV) protection. However, traditional steroidal MRAs, such as Spironolactone and Eplerenone, are limited by nonselective receptor binding, leading to dose-dependent hyperkalemia (19%-24% incidence in CKD) and endocrine side effects (e.g., gynecomastia in 10%-15% of patients) that restrict their use in high-risk populations [<a href="#REF5" class="usa-link" aria-describedby="REF5">5</a>-<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>].</p>
<p>The rising prevalence of cardiorenal diseases, fuelled by aging populations and epidemics of type 2 diabetes mellitus (T2DM) and hypertension, has intensified the need for MRAs that balance efficacy with safety [<a href="#REF1" class="usa-link" aria-describedby="REF1">1</a>,<a href="#REF2" class="usa-link" aria-describedby="REF2">2</a>]. Steroidal MRAs, while foundational, often necessitate discontinuation or dose reduction in advanced CKD due to hyperkalemia risk, leaving many patients undertreated [<a href="#REF5" class="usa-link" aria-describedby="REF5">5</a>,<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>]. Finerenone, a third-generation nonsteroidal MRA, emerged from targeted drug design to address these limitations. In vitro studies demonstrated 800-fold higher MR selectivity over androgen and progesterone receptors compared to Spironolactone, minimizing off-target hormonal interactions [<a href="#REF8" class="usa-link" aria-describedby="REF8">8</a>,<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>]. Preclinical models further revealed balanced tissue distribution, favoring cardiac and renal MR blockade while reducing renal tubular potassium retention, a critical advance for CKD populations [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>,<a href="#REF10" class="usa-link" aria-describedby="REF10">10</a>]. These mechanistic advantages translated clinically: phase 3 trials (FIDELIO-DKD, FIGARO-DKD) demonstrated finerenone’s ability to reduce the risk of kidney failure by 18% (hazard ratio, HR, 0.82; 95% confidence interval, CI, 0.73-0.93) and CV events by 14% (HR, 0.86; 95% CI, 0.75-0.99) in patients with T2DM and CKD, with hyperkalemia rates of 14% vs. 19%-24% for Spironolactone [<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>,<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>,<a href="#REF12" class="usa-link" aria-describedby="REF12">12</a>].</p>
<p>This review examines the pharmacology, clinical efficacy, and safety profile of Finerenone, contextualizing its role within the evolving landscape of MR antagonism. It emphasizes finerenone’s potential to address unmet therapeutic needs in CKD and HF, while also acknowledging ongoing challenges, such as the risk of hyperkalemia in advanced CKD and the need for long-term mortality data.</p></section><section id="sec2"><h2 class="pmc_sec_title">Review</h2>
<p>Evolution of MRAs: from spironolactone to finerenone</p>
<p>The evolution of MRAs has been driven by a deepening understanding of aldosterone’s pathophysiological role and the need to address limitations of prior therapies. Aldosterone, a key effector of the renin-angiotensin-aldosterone system (RAAS), promotes sodium retention, potassium excretion, and vascular remodeling, contributing to hypertension, fibrosis, and end-organ damage in CKD and HF [<a href="#REF3" class="usa-link" aria-describedby="REF3">3</a>,<a href="#REF4" class="usa-link" aria-describedby="REF4">4</a>]. Early recognition of aldosterone’s harmful effects, such as its role in cardiac fibrosis and renal inflammation, established MR antagonism as a therapeutic target [<a href="#REF13" class="usa-link" aria-describedby="REF13">13</a>,<a href="#REF14" class="usa-link" aria-describedby="REF14">14</a>]. However, translating this knowledge into safe and effective therapies required iterative advancements in receptor selectivity and pharmacokinetics.</p>
<p>First-Generation MRA: Spironolactone</p>
<p>Discovered in the 1960s, Spironolactone became the first clinically viable MRA. While it effectively blocked aldosterone’s effects, its steroidal structure conferred nonselective binding to androgen and progesterone receptors [<a href="#REF5" class="usa-link" aria-describedby="REF5">5</a>]. This off-target activity caused dose-limiting endocrine side effects, including gynecomastia (10%-15% of male patients) and menstrual irregularities, which restricted its long-term use [<a href="#REF5" class="usa-link" aria-describedby="REF5">5</a>,<a href="#REF6" class="usa-link" aria-describedby="REF6">6</a>]. Despite these drawbacks, Spironolactone demonstrated mortality benefits in severe HF (Randomized Aldactone Evaluation Study, RALES, trial, 30% reduction [<a href="#REF6" class="usa-link" aria-describedby="REF6">6</a>]), validating MR blockade as a strategy. However, its nonselectivity and hyperkalemia risk in CKD underscored the need for improved agents.</p>
<p>Second-Generation MRA: Eplerenone</p>
<p>Eplerenone, developed in the 2000s, retained a steroidal backbone but exhibited higher MR selectivity, minimizing sex hormone receptor binding [<a href="#REF15" class="usa-link" aria-describedby="REF15">15</a>]. This reduced endocrine toxicity, enabling broader use in postmyocardial infarction HF (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study, EPHESUS, trial: 15% mortality reduction [<a href="#REF15" class="usa-link" aria-describedby="REF15">15</a>]). However, its steroidal nature still predisposed patients to hyperkalemia, particularly in renal impairment, due to lipophilicity-driven renal tubular accumulation [<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>,<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>]. These limitations highlighted the need for nonsteroidal MRAs with optimized tissue distribution.</p>
<p>Third-Generation MRA: Finerenone</p>
<p>Finerenone, a 2010s innovation, was designed to overcome steroidal shortcomings. Its dibenzothiophene-based, nonsteroidal structure eliminated sex hormone receptor binding, resolving endocrine side effects [<a href="#REF5" class="usa-link" aria-describedby="REF5">5</a>,<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>]. Preclinical studies revealed a balanced tissue distribution, preferentially targeting cardiac and renal MRs, which reduced renal potassium retention and the risk of hyperkalemia compared to steroidal MRAs [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>,<a href="#REF10" class="usa-link" aria-describedby="REF10">10</a>]. Phase 3 trials (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease, FIDELIO-DKD, and Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease, FIGARO-DKD) confirmed its cardiorenal benefits in T2DM and CKD, with hyperkalemia rates comparable to placebo when managed proactively [<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>,<a href="#REF12" class="usa-link" aria-describedby="REF12">12</a>]. This evolution reflects a direct response to prior generations: structural refinement to enhance selectivity, mitigate toxicity, and align pharmacokinetics with pathophysiological targets.</p>
<p>Each MRA generation emerged from lessons learned: Spironolactone’s efficacy established MR antagonism as vital, Eplerenone’s selectivity addressed hormonal toxicity, and Finerenone’s nonsteroidal design optimized safety for chronic use in high-risk populations. This progression underscores how translational insights into aldosterone’s mechanisms directly informed therapeutic innovation.</p>
<p>Finerenone mechanism of action and pharmacokinetics</p>
<p>Mechanistic Rationale</p>
<p>Finerenone is a potent, orally available, nonsteroidal MRA that selectively blocks aldosterone and cortisol binding to MR without modulating 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) activity [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>,<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>]. Unlike steroidal MRAs (e.g., Spironolactone and Eplerenone), which may indirectly influence cortisol-MR interactions via enzymatic pathways, Finerenone directly competes with aldosterone and cortisol for MR binding, thereby inhibiting proinflammatory (e.g., nuclear factor kappa B, NF-κB) and profibrotic (e.g., transforming growth factor beta, TGF-β) signaling cascades [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>,<a href="#REF14" class="usa-link" aria-describedby="REF14">14</a>]. This mechanism is distinct from pathological conditions characterized by impaired 11β-HSD2 activity, where cortisol aberrantly activates MR due to insufficient conversion to cortisone [<a href="#REF14" class="usa-link" aria-describedby="REF14">14</a>,<a href="#REF16" class="usa-link" aria-describedby="REF16">16</a>]. By bypassing enzymatic modulation, Finerenone avoids the risk of cortisol-driven MR overactivation, a harmful consequence of 11β-HSD2 inhibition observed in other therapeutic strategies [<a href="#REF14" class="usa-link" aria-describedby="REF14">14</a>].</p>
<p>Finerenone’s unique dibenzothiophene-based structure confers stronger MR affinity and slower dissociation kinetics compared to aldosterone, ensuring prolonged receptor blockade [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>]. Critically, its nonsteroidal design eliminates antiandrogenic activity (20-fold weaker than Spironolactone), resolving a key limitation of first-generation MRAs [<a href="#REF5" class="usa-link" aria-describedby="REF5">5</a>,<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>].</p>
<p>Clinical Validation</p>
<p>The structural and mechanistic advantages of Finerenone translate to improved clinical tolerability. Phase 3 trials demonstrated negligible endocrine side effects (e.g., ≤1% gynecomastia vs. 10%-15% with Spironolactone), validating its minimal off-target interactions with androgen or progesterone receptors [<a href="#REF5" class="usa-link" aria-describedby="REF5">5</a>,<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>,<a href="#REF17" class="usa-link" aria-describedby="REF17">17</a>]. Furthermore, Finerenone’s balanced tissue distribution, prioritizing cardiac and renal MR over adipose tissue, reduces renal tubular potassium retention, resulting in lower hyperkalemia incidence (14% vs. 19%-24% with Spironolactone) when managed with protocol-driven dose adjustments [<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>,<a href="#REF10" class="usa-link" aria-describedby="REF10">10</a>,<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>]. These outcomes confirm its mechanistic promise: selective MR antagonism without enzymatic interference or systemic hormonal toxicity.</p>
<p>Pharmacokinetic Profile</p>
<p>Finerenone exhibits rapid absorption, reaching peak plasma concentrations (Tmax) within two hours, which contributes to its prompt onset of therapeutic action. Its high oral bioavailability (~70%) ensures sufficient systemic exposure to achieve clinical efficacy [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>,<a href="#REF10" class="usa-link" aria-describedby="REF10">10</a>]. The prolonged terminal elimination half-life (~20 hours) supports once-daily dosing, enhancing patient adherence and reducing dosing frequency-related errors [<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>,<a href="#REF18" class="usa-link" aria-describedby="REF18">18</a>]. Finerenone undergoes hepatic phase 1 metabolism via cytosolic enzymes, with subsequent biliary excretion of metabolites, minimizing reliance on renal clearance [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>,<a href="#REF18" class="usa-link" aria-describedby="REF18">18</a>]. This pharmacokinetic profile reduces the risk of drug accumulation in patients with renal impairment, a critical advantage for its use in CKD populations [<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>,<a href="#REF18" class="usa-link" aria-describedby="REF18">18</a>].</p>
<p>Food intake, particularly high-fat meals, delays the absorption rate of finerenone, prolonging the time to reach Tmax by approximately one to two hours. However, total systemic exposure remains unaffected, ensuring no compromise in overall efficacy [<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>]. This allows flexibility in administration with or without food, though consistent dosing relative to meals is recommended to maintain stable plasma concentrations. Notably, while high-fat meals may transiently delay metabolite clearance, this has no clinically significant impact on therapeutic outcomes [<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>].</p>
<p>Clinical applications of finerenone</p>
<p>The MR plays a central role in the development and progression of chronic HF, CKD, and proteinuria in primary and secondary glomerular diseases [<a href="#REF3" class="usa-link" aria-describedby="REF3">3</a>]. Additionally, the therapeutic utility of both steroidal and nonsteroidal MRAs is significantly limited by the risk of hyperkalemia, a common and potentially serious adverse effect [<a href="#REF6" class="usa-link" aria-describedby="REF6">6</a>].</p>
<p>As a potential solution, Finerenone, a selective nonsteroidal MRA, has emerged with promising results. Notably, the structure of Finerenone is chemically unrelated to other MRAs, setting it apart. Preclinical and clinical studies have demonstrated its comparatively lower risk of inducing hyperkalemia, a longstanding challenge with traditional MRAs, with trial data showing a 14% incidence vs. 19%-24% with Spironolactone, alongside protocol-driven management to mitigate this risk [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>]. Furthermore, Finerenone has been shown to be a highly effective therapeutic option in delaying CKD progression and reducing the risk of kidney failure in patients with T2DM and CKD, as demonstrated in the FIDELIO-DKD trial [<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>].</p>
<p>Findings from one early-phase clinical study into Finerenone 's effect on CKD indicated significant benefits in systolic and diastolic blood pressure and the left ventricular mass seen in patients with nondiabetic proteinuric kidney disease that had not previously been observed with steroidal MRAs [<a href="#REF19" class="usa-link" aria-describedby="REF19">19</a>]. These remarkable results from the initial study prompted further investigation in advanced clinical trials, which demonstrated renoprotection by Finerenone in patients with T2DM and CKD, heart failure with reduced ejection fraction (HFrEF), and increased CV risk [<a href="#REF6" class="usa-link" aria-describedby="REF6">6</a>,<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>,<a href="#REF20" class="usa-link" aria-describedby="REF20">20</a>]. These compelling findings strongly suggest that selective, nonsteroidal MRAs could potentially revolutionize treatment in the aforementioned settings, offering myriad advantages, including a notable reduction in the occurrence of hyperkalemia [<a href="#REF18" class="usa-link" aria-describedby="REF18">18</a>].</p>
<p>Treatment of Chronic Kidney Disease</p>
<p>The FIDELIO-DKD trial, a phase 3 randomized, double-blind, placebo-controlled study, evaluated Finerenone in 5,734 patients with CKD and T2DM. Over a median follow-up of 2.6 years, Finerenone significantly reduced the primary composite outcome of kidney failure, sustained ≥40% decline in estimated glomerular filtration rate (eGFR), or renal death by 18% (HR, 0.82; 95% CI, 0.73-0.93; p = 0.001) compared to placebo. Additionally, CV events (death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for HF) were reduced by 14% (HR, 0.86; 95% CI, 0.75-0.99; p = 0.034), underscoring its cardiorenal benefits [<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>].</p>
<p>The FIGARO-DKD trial extended these findings to 7,437 patients with earlier stage CKD and T2DM. Finerenone reduced the risk of CV events (death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for HF) by 14% (HR, 0.87; 95% CI, 0.76-0.98; p = 0.026) and slowed CKD progression, demonstrating efficacy across a broader CKD spectrum [<a href="#REF12" class="usa-link" aria-describedby="REF12">12</a>].</p>
<p>The prespecified Finerenone in Chronic Kidney Disease and Type 2 Diabetes (FIDELITY) pooled analysis (combining FIDELIO-DKD and FIGARO-DKD) included 13,026 patients and confirmed Finerenone’s consistent benefits: a 23% reduction in kidney outcomes (HR, 0.77; 95% CI, 0.67-0.88) and a 14% reduction in CV events (HR, 0.86; 95% CI, 0.78-0.95), irrespective of baseline CKD severity [<a href="#REF21" class="usa-link" aria-describedby="REF21">21</a>]. These trials establish Finerenone as a pivotal therapy for mitigating both renal and CV risks in patients with CKD and T2DM.</p>
<p>Management of HF With Reduced Ejection Fraction</p>
<p>HFrEF is a serious CV disorder with high morbidity and mortality, especially when patients are hospitalized. Though the survival of patients with HFrEF has significantly improved over the last two decades, it remains exceedingly poor and discouraging [<a href="#REF1" class="usa-link" aria-describedby="REF1">1</a>]. Furthermore, the prevailing pandemic of diabetes mellitus and related complications like hypertension and obesity has emphasized the urgent and imperative need for the implementation of effective management strategies in the treatment of HF [<a href="#REF2" class="usa-link" aria-describedby="REF2">2</a>]. In this regard, MRAs have emerged as a promising therapeutic option for this debilitating condition [<a href="#REF6" class="usa-link" aria-describedby="REF6">6</a>].</p>
<p>MRAs primarily function by selectively targeting and neutralizing the MRs that are prominently expressed in crucial CV sites such as the heart, vasculature, and kidneys. By doing so, they successfully attenuate the deleterious effects of fibrosis and inflammation, which are known to exacerbate HF and impede its treatment outcomes [<a href="#REF13" class="usa-link" aria-describedby="REF13">13</a>]. It is important to note that the activation of MR occurs in response to the action of aldosterone, a hormone that is primarily synthesized and secreted from the zona glomerulosa of the adrenal gland [<a href="#REF22" class="usa-link" aria-describedby="REF22">22</a>]. Notably, aldosterone predominantly functions as a sodium-retaining hormone, which, in turn, contributes to the pathophysiology of HF [<a href="#REF3" class="usa-link" aria-describedby="REF3">3</a>]. Accumulating evidence has consistently demonstrated a substantial increase in aldosterone levels among patients afflicted with HF, as well as in experimental rat models [<a href="#REF4" class="usa-link" aria-describedby="REF4">4</a>]. Moreover, it has been ascertained that plasma aldosterone levels are closely associated with adverse health outcomes in individuals suffering from HF [<a href="#REF23" class="usa-link" aria-describedby="REF23">23</a>].</p>
<p>MRAs not only decrease mortality and morbidity in patients with HFrEF but also improve health outcomes in patients with hypertension and CKD [<a href="#REF15" class="usa-link" aria-describedby="REF15">15</a>]. However, hyperkalemia is a major adverse effect of MRA therapy because it decreases renal function and renal excretion of potassium [<a href="#REF5" class="usa-link" aria-describedby="REF5">5</a>]. Despite significant advancements over six decades, the development of novel MRAs has been challenged not only by scientific hurdles, such as optimizing receptor selectivity and minimizing off-target effects, but also by practical barriers, including commercial viability, regulatory complexities, and pharmacokinetic challenges [<a href="#REF18" class="usa-link" aria-describedby="REF18">18</a>,<a href="#REF24" class="usa-link" aria-describedby="REF24">24</a>]. Therefore, there is an urgent need for further research and innovation in this field to discover new therapeutic options that can successfully target and modulate MR, leading to improved outcomes for patients with HFrEF [<a href="#REF24" class="usa-link" aria-describedby="REF24">24</a>]. MRAs have shown significant promise in improving HFrEF patient outcomes [<a href="#REF22" class="usa-link" aria-describedby="REF22">22</a>], but further exploration and development of novel therapies are necessary to address the limitations and adverse effects associated with current treatment options.</p>
<p>Comparative mechanisms and distinction of finerenone among MRAs</p>
<p>Finerenone represents a significant therapeutic advancement as a nonsteroidal, selective MRA, designed to overcome the limitations of traditional steroidal MRAs such as Spironolactone and Eplerenone. Its unique dibenzothiophene-based structure confers high selectivity for MR while exhibiting negligible affinity for androgen or progesterone receptors, thereby minimizing endocrine-related adverse effects like gynecomastia and menstrual irregularities observed with Spironolactone [<a href="#REF25" class="usa-link" aria-describedby="REF25">25</a>]. In contrast, Eplerenone, a second-generation steroidal MRA, retains residual glucocorticoid receptor binding, which limits its safety in renal impairment, while Spironolactone’s moderate receptor selectivity and strong antiandrogenic/progestogenic activity contribute to hormonal toxicity [<a href="#REF5" class="usa-link" aria-describedby="REF5">5</a>,<a href="#REF15" class="usa-link" aria-describedby="REF15">15</a>].</p>
<p>Mechanistically, Finerenone induces distinct conformational changes in MR by binding to a unique hydrophobic pocket, preferentially inhibiting proinflammatory (e.g., NF-κB) and profibrotic (e.g., TGF-β) signaling pathways more effectively than steroidal MRAs [<a href="#REF26" class="usa-link" aria-describedby="REF26">26</a>]. This targeted antagonism contrasts with the broader inhibition of sodium retention and potassium excretion by Spironolactone and Eplerenone, which exacerbates hyperkalemia risk [<a href="#REF6" class="usa-link" aria-describedby="REF6">6</a>,<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>]. Furthermore, Finerenone’s physicochemical properties, including reduced lipophilicity and balanced tissue distribution, minimize accumulation in adipose tissue and renal tubules, avoiding the systemic toxicity associated with the widespread penetration of steroidal MRAs [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>,<a href="#REF10" class="usa-link" aria-describedby="REF10">10</a>].</p>
<p>Clinically, Finerenone demonstrates cardiorenal benefits in patients with T2DM and CKD, a high-risk population with overlapping metabolic and renal dysfunction. In the FIDELIO-DKD trial, Finerenone reduced the composite risk of kidney failure, sustained eGFR decline, or renal death by 18%, alongside a 14% reduction in CV events [<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>]. The FIGARO-DKD trial further highlighted its CV benefits, showing a 14% risk reduction in CV mortality and morbidity across broader CKD stages [<a href="#REF12" class="usa-link" aria-describedby="REF12">12</a>]. While direct comparisons with steroidal MRAs are limited by differing trial populations, Eplerenone’s 15% mortality reduction was observed in post-myocardial infarction HF (EPHESUS trial), Spironolactone’s 30% mortality benefit was in severe HF (RALES trial), and Finerenone’s improved tolerability in its target population is notable [<a href="#REF6" class="usa-link" aria-describedby="REF6">6</a>,<a href="#REF15" class="usa-link" aria-describedby="REF15">15</a>].</p>
<p>A key advantage of Finerenone lies in its safety profile. Hyperkalemia incidence with Finerenone (14%) is lower than with Spironolactone (19%-24%) and comparable to placebo, attributed to its balanced tissue distribution (preferential targeting of cardiac and renal MR) and reduced lipophilicity, which minimizes renal accumulation [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>-<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>]. While Finerenone exhibits a comparatively favorable safety profile relative to steroidal MRAs, clinically relevant risks such as hyperkalemia (14% incidence in trials) and hypotension necessitate vigilant monitoring and protocol-driven management [<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>,<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>]. These risks, though lower than those associated with Spironolactone or Eplerenone, underscore the importance of regular serum potassium checks and dose adjustments in high-risk populations. For example, Spironolactone’s high lipophilicity drives widespread tissue penetration, contributing to off-target hormonal effects (e.g., gynecomastia in 10%-15% of patients) and renal potassium retention. In contrast, Finerenone’s selective distribution mitigates these issues [<a href="#REF5" class="usa-link" aria-describedby="REF5">5</a>,<a href="#REF17" class="usa-link" aria-describedby="REF17">17</a>].</p>
<p>Despite this, hyperkalemia remains the most common reason for discontinuation in Finerenone trials (2.3% in FIDELIO-DKD vs. 0.9% with placebo). Finerenone’s reduced lipophilicity enables proactive management strategies, such as dose reduction (halving the dose for serum potassium &gt;5.5 mmol/L), temporary discontinuation for severe hyperkalemia (&gt;6 mmol/L), dietary modifications, and routine monitoring, to succeed with fewer complications than steroidal MRAs [<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>,<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>,<a href="#REF27" class="usa-link" aria-describedby="REF27">27</a>].</p>
<p>Beyond hyperkalemia, Finerenone’s endocrine safety is further evidenced by low rates of gynecomastia (≤1% vs. 10%-15% with Spironolactone), underscoring its potential as a safer long-term therapy in CKD and diabetes populations [<a href="#REF5" class="usa-link" aria-describedby="REF5">5</a>,<a href="#REF17" class="usa-link" aria-describedby="REF17">17</a>]. Tolerability data from trials such as Mineralocorticoid Receptor antagonist Tolerability Study-Heart Failure and FIDELITY underscore Finerenone’s suitability for long-term use. Hyperkalemia occurred more frequently with Finerenone than placebo (14% vs. 9%), but rates of other adverse events, including gastrointestinal disturbances and urinary tract infections, were comparable between the groups [<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>]. Proactive monitoring and dose adjustments minimized severe hyperkalemia-related discontinuations (2.3% vs. 0.9% placebo), reinforcing its manageable safety profile in high-risk cohorts [<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>,<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>]. Table <a href="#TAB1" class="usa-link">1</a> summarizes the pharmacological and clinical distinctions between Finerenone and steroidal MRAs.</p>
<section class="tw xbox font-sm" id="TAB1"><h3 class="obj_head">Table 1. The pharmacological and clinical distinctions between finerenone and steroidal MRAs.</h3>
<div class="caption p">
<p><sup>*</sup>Lower risk due to balanced tissue distribution; incidence based on pooled data from FIDELIO-DKD and FIGARO-DKD trials [<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>,<a href="#REF12" class="usa-link" aria-describedby="REF12">12</a>], risk mitigated by balanced tissue distribution and protocol-driven dose adjustments</p>
<p><sup>¥</sup>Rates from EPHESUS trial in post-MI HF populations [<a href="#REF15" class="usa-link" aria-describedby="REF15">15</a>], risk persists in advanced CKD due to residual renal accumulation</p>
<p><sup>#</sup>Higher risk in CKD patients due to lipophilic accumulation and reduced potassium excretion, risk is dose- and CKD-dependent; incidence ranges reflect dose-dependent risk (e.g., 25-50 mg/day) [<a href="#REF5" class="usa-link" aria-describedby="REF5">5</a>,<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>]</p>
<p><sup>§</sup>Balanced means preferential targeting of the heart/kidneys</p>
<p><sup>‡</sup>Widespread means lipophilic-driven penetration into adipose/renal tissue</p>
<p>CKD: chronic kidney disease; CV: cardiovascular; FIDELIO-DKD: Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease; EPHESUS: Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study; RALES: Randomized Aldactone Evaluation Study; MRA: mineralocorticoid receptor antagonist; FIGARO-DKD: Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease; MI: myocardial infarction; HF: heart failure</p>
</div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"><tbody>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">Feature</td>
<td rowspan="1" colspan="1">Finerenone</td>
<td rowspan="1" colspan="1">Eplerenone</td>
<td rowspan="1" colspan="1">Spironolactone</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Generation</td>
<td rowspan="1" colspan="1">Third</td>
<td rowspan="1" colspan="1">Second</td>
<td rowspan="1" colspan="1">First</td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">Structure</td>
<td rowspan="1" colspan="1">Nonsteroidal</td>
<td rowspan="1" colspan="1">Steroidal</td>
<td rowspan="1" colspan="1">Steroidal</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Mineralocorticoid receptor selectivity</td>
<td rowspan="1" colspan="1">High</td>
<td rowspan="1" colspan="1">Moderate to high</td>
<td rowspan="1" colspan="1">Moderate</td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">Affinity to sex hormone receptors</td>
<td rowspan="1" colspan="1">Low (minimal off-target)</td>
<td rowspan="1" colspan="1">Low</td>
<td rowspan="1" colspan="1">High (androgen/progesterone)</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Hyperkalemia incidence</td>
<td rowspan="1" colspan="1">Lower (14%)<sup>*</sup>
</td>
<td rowspan="1" colspan="1">Moderate (15%-18%)<sup>¥</sup>
</td>
<td rowspan="1" colspan="1">Higher (19%-24%)<sup>#</sup>
</td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">Tissue penetration</td>
<td rowspan="1" colspan="1">Balanced (vascular-focused)<sup>§</sup>
</td>
<td rowspan="1" colspan="1">Moderate</td>
<td rowspan="1" colspan="1">Widespread (lipophilic)<sup>‡</sup>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Endocrine side effects</td>
<td rowspan="1" colspan="1">≤1%</td>
<td rowspan="1" colspan="1">&lt;5%</td>
<td rowspan="1" colspan="1">Dose-dependent gynecomastia (10%-15% at &gt;50 mg/day), menstrual irregularities</td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">Diuretic effect</td>
<td rowspan="1" colspan="1">Weak</td>
<td rowspan="1" colspan="1">Weak</td>
<td rowspan="1" colspan="1">Strong (K<sup>+</sup>-sparing)</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Key considerations</td>
<td rowspan="1" colspan="1">Preferential renal/heart targeting</td>
<td rowspan="1" colspan="1">Caution in advanced CKD</td>
<td rowspan="1" colspan="1">Dose adjustments in CKD; monitor K<sup>+</sup> level</td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">Mortality reduction</td>
<td rowspan="1" colspan="1">14% CV events (FIDELIO-DKD)</td>
<td rowspan="1" colspan="1">15% CV death (EPHESUS)</td>
<td rowspan="1" colspan="1">30% all-cause (RALES)</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Hospitalization</td>
<td rowspan="1" colspan="1">14% reduction</td>
<td rowspan="1" colspan="1">17% reduction</td>
<td rowspan="1" colspan="1">35% reduction</td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">Renoprotection</td>
<td rowspan="1" colspan="1">18% kidney risk reduction</td>
<td rowspan="1" colspan="1">No significant CKD benefit</td>
<td rowspan="1" colspan="1">Limited data in CKD</td>
</tr>
</tbody></table></div>
<div class="p text-right font-secondary"><a href="table/TAB1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p>Finerenone key clinical trials and studies</p>
<p>Finerenone has been extensively studied in clinical trials across diverse populations with CKD, T2DM, and HF. Below is a chronological overview of key trials, highlighting Finerenone’s therapeutic potential and safety profile. A summary table is provided for quick reference (Table <a href="#TAB2" class="usa-link">2</a>).</p>
<section class="tw xbox font-sm" id="TAB2"><h3 class="obj_head">Table 2. Key finerenone clinical trials.</h3>
<div class="caption p"><p>ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; ARTS-DN: Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy; CI: confidence interval; CKD: chronic kidney disease; CV: cardiovascular; eGFR: estimated glomerular filtration rate; FIDELIO-DKD: Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease; FIDELITY: Finerenone in Chronic Kidney Disease and Type 2 Diabetes; FIGARO-DKD: Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease; FINEARTS-HF: FINerenone trial to investigate Efficacy and sAfety superioR to placebo in paTientS with Heart Failure; HFmrEF/HFpEF: heart failure with mildly reduced/preserved ejection fraction; LVEF: left ventricular ejection fraction; HR: hazard ratio; MRA: mineralocorticoid receptor antagonist; T1DM: type 1 diabetes mellitus; T2DM: type 2 diabetes mellitus; UACR: urinary albumin-to-creatinine ratio; FINE-ONE: FINErenone in participants with type-ONE diabetes and chronic kidney disease</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"><tbody>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">Trial name</td>
<td rowspan="1" colspan="1">Phase</td>
<td rowspan="1" colspan="1">Year</td>
<td rowspan="1" colspan="1">Population</td>
<td rowspan="1" colspan="1">Intervention</td>
<td rowspan="1" colspan="1">Key outcomes</td>
<td rowspan="1" colspan="1">Safety</td>
<td rowspan="1" colspan="1">Significance</td>
</tr>
<tr>
<td rowspan="1" colspan="1">ARTS-DN [<a href="#REF28" class="usa-link" aria-describedby="REF28">28</a>] (earlier-stage, dose-finding study)</td>
<td rowspan="1" colspan="1">2b</td>
<td rowspan="1" colspan="1">2014</td>
<td rowspan="1" colspan="1">823 patients, T2DM + persistent albuminuria (UACR ≥30 mg/g)</td>
<td rowspan="1" colspan="1">Finerenone (1.25-20 mg/day) vs. placebo</td>
<td rowspan="1" colspan="1">38% reduction in UACR at highest dose (p &lt; 0.001)</td>
<td rowspan="1" colspan="1">Hyperkalemia is dose-dependent but manageable; low discontinuation rates</td>
<td rowspan="1" colspan="1">First evidence of Finerenone’s renoprotective effects; supported phase 3 trials</td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">FIDELIO-DKD [<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>] (used time-to-first-event composites)</td>
<td rowspan="1" colspan="1">3</td>
<td rowspan="1" colspan="1">2020</td>
<td rowspan="1" colspan="1">5,734 patients, T2DM + advanced CKD (eGFR 25-60 mL/minute, UACR ≥30 mg/g)</td>
<td rowspan="1" colspan="1">Finerenone vs. placebo (+ ACEi/ARB)</td>
<td rowspan="1" colspan="1">18% reduction in kidney failure/sustained eGFR decline/renal death (HR, 0.82; p = 0.001); 14% reduction in CV events (HR, 0.86; p = 0.034)</td>
<td rowspan="1" colspan="1">Hyperkalemia: 18.3% vs. 9% (placebo); discontinuation: 2.3% vs. 0.9%</td>
<td rowspan="1" colspan="1">Established Finerenone’s dual cardiorenal benefits in advanced CKD</td>
</tr>
<tr>
<td rowspan="1" colspan="1">FIGARO-DKD [<a href="#REF12" class="usa-link" aria-describedby="REF12">12</a>] (used time-to-first-event composites)</td>
<td rowspan="1" colspan="1">3</td>
<td rowspan="1" colspan="1">2021</td>
<td rowspan="1" colspan="1">7,437 patients, T2DM + earlier CKD (eGFR ≥25 mL/minute, UACR ≥30 mg/g)</td>
<td rowspan="1" colspan="1">Finerenone vs. placebo (+ACEi/ARB)</td>
<td rowspan="1" colspan="1">Time-to-first-event composites: 13% reduction in CV events (HR, 0.87; p = 0.03); slowed CKD progression (nonsignificant trend)</td>
<td rowspan="1" colspan="1">Hyperkalemia: 10.8% vs. 5.3% (placebo)</td>
<td rowspan="1" colspan="1">Extended Finerenone’s CV benefits to earlier CKD stages</td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">FIDELITY [<a href="#REF29" class="usa-link" aria-describedby="REF29">29</a>]</td>
<td rowspan="1" colspan="1">Pooled</td>
<td rowspan="1" colspan="1">2022</td>
<td rowspan="1" colspan="1">13,026 patients from FIDELIO-DKD + FIGARO-DKD (broad CKD stages)</td>
<td rowspan="1" colspan="1">Pooled analysis</td>
<td rowspan="1" colspan="1">23% reduction in kidney outcomes (HR, 0.77; 95% CI, 0.67-0.88); 14% reduction in CV events (HR, 0.86; 95% CI, 0.78-0.95)</td>
<td rowspan="1" colspan="1">Consistent safety profile across trials</td>
<td rowspan="1" colspan="1">Confirmed Finerenone’s efficacy across CKD severities; dual-organ protection</td>
</tr>
<tr>
<td rowspan="1" colspan="1">FINEARTS-HF [<a href="#REF27" class="usa-link" aria-describedby="REF27">27</a>] (used total HF events + CV death composite endpoint)</td>
<td rowspan="1" colspan="1">3</td>
<td rowspan="1" colspan="1">2024</td>
<td rowspan="1" colspan="1">6,215 patients, HFmrEF/HFpEF (LVEF &gt;40%)</td>
<td rowspan="1" colspan="1">Finerenone vs. placebo</td>
<td rowspan="1" colspan="1">12% reduction in total HF events + CV death (HR 0.88; p = 0.02)</td>
<td rowspan="1" colspan="1">Hyperkalemia: 10.5% vs. 4.7% (placebo)</td>
<td rowspan="1" colspan="1">First MRA to show efficacy in HFpEF, a population with limited therapies</td>
</tr>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">FINE-ONE [<a href="#REF30" class="usa-link" aria-describedby="REF30">30</a>]</td>
<td rowspan="1" colspan="1">3</td>
<td rowspan="1" colspan="1">Ongoing</td>
<td rowspan="1" colspan="1">1,650 adults, T1DM + CKD (UACR ≥200 mg/g or eGFR 25-90 mL/minutes)</td>
<td rowspan="1" colspan="1">Finerenone vs. placebo (+ACEi/ARB)</td>
<td rowspan="1" colspan="1">Primary outcome: time to kidney failure/sustained eGFR decline/renal death</td>
<td rowspan="1" colspan="1">Monitoring hyperkalemia and renal safety</td>
<td rowspan="1" colspan="1">Aims to extend Finerenone’s benefits to T1DM, a high-risk, understudied population</td>
</tr>
</tbody></table></div>
<div class="p text-right font-secondary"><a href="table/TAB2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p>ARTS-DN (2014)</p>
<p>The Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) phase 2b trial evaluated Finerenone’s safety and efficacy in 823 patients with T2DM and albuminuric CKD [<a href="#REF28" class="usa-link" aria-describedby="REF28">28</a>]. Participants received varying Finerenone doses (1.25-20 mg/day) or placebo alongside RAAS inhibitors. Results showed a dose-dependent 38% reduction in albuminuria (urinary albumin-to-creatinine ratio, UACR) at the highest dose (p &lt; 0.001), with manageable hyperkalemia. ARTS-DN provided foundational evidence for Finerenone’s renoprotective potential, paving the way for phase 3 trials.</p>
<p>FIDELIO-DKD (2020)</p>
<p>The FIDELIO-DKD pivotal phase 3 trial enrolled 5,734 patients with T2DM and advanced CKD. Over 2.6 years, Finerenone reduced the primary renal composite outcome (kidney failure, ≥40% eGFR decline, renal death) by 18% (HR, 0.82; p = 0.001) and the CV composite outcome (death, myocardial infarction, stroke, and HF hospitalization) by 14% (HR, 0.86; p = 0.034). Hyperkalemia occurred in 18.3% of Finerenone-treated patients vs. 9% with placebo, but discontinuations were rare (2.3%). Management strategies included protocol-driven dose reductions (from 20 to 10 mg daily) for serum potassium levels &gt;5.5 mmol/L, temporary discontinuation for levels &gt;6.0 mmol/L, and dietary counseling to restrict potassium intake. Regular monitoring (baseline, four weeks, and every four months thereafter) ensured early detection and intervention [<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>,<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>]. These measures underscore Finerenone’s manageable safety profile in advanced CKD.</p>
<p>FIGARO-DKD (2021)</p>
<p>In 7,437 patients with T2DM and earlier stage CKD, Finerenone reduced CV events by 14% (HR, 0.87; p = 0.03) over 3.4 years with a trend toward slower CKD progression [<a href="#REF12" class="usa-link" aria-describedby="REF12">12</a>]. Hyperkalemia rates were lower (10.8% vs. 5.3%) than in FIDELIO-DKD, likely due to the inclusion of earlier stage CKD patients. Proactive management included prespecified dose adjustments (e.g., halving the dose for potassium &gt;5.5 mmol/L), monthly serum potassium monitoring during the first year, and patient education on avoiding high-potassium diets and nephrotoxic agents [<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>,<a href="#REF12" class="usa-link" aria-describedby="REF12">12</a>]. Only 1.2% of participants discontinued treatment due to hyperkalemia, reflecting effective mitigation strategies. While renal benefits were less pronounced than in FIDELIO-DKD, this trial highlighted Finerenone’s broad applicability across CKD stages.</p>
<p>FIDELITY (2022)</p>
<p>Combining 13,026 patients, pooled analysis of FIDELIO-DKD and FIGARO-DKD (FIDELITY) confirmed Finerenone’s 23% reduction in kidney outcomes (HR, 0.77; 95% CI, 0.67-0.88) and 14% reduction in CV events (HR, 0.86; 95% CI, 0.78-0.95) [<a href="#REF29" class="usa-link" aria-describedby="REF29">29</a>]. Benefits were consistent across CKD stages, reinforcing Finerenone’s dual cardiorenal protection in high-risk T2DM populations.</p>
<p>FINEARTS-HF (2024)</p>
<p>FINerenone trial to investigate Efficacy and sAfety superioR to placebo in paTientS with Heart Failure (FINEARTS-HF) phase 3 trial enrolled 6,215 heart failure with mildly reduced/preserved ejection fraction (HFmrEF/HFpEF) patients [<a href="#REF27" class="usa-link" aria-describedby="REF27">27</a>]. Finerenone reduced total HF events and CV death by 12% (HR, 0.88; p = 0.02), offering hope for a population with limited therapeutic options. Hyperkalemia was more frequent in the Finerenone group (10.5%) compared with placebo (4.7%), but severe hyperkalemia (&gt;6 mmol/L) occurred in only 1.8% of patients. Protocolized management included temporary dose interruption, potassium-lowering therapies (e.g., diuretics or sodium polystyrene sulfonate), and intensified monitoring (biweekly during dose titration). No fatalities were attributed to hyperkalemia, demonstrating the feasibility of Finerenone in HFmrEF/HFpEF with vigilant oversight [<a href="#REF27" class="usa-link" aria-describedby="REF27">27</a>,<a href="#REF31" class="usa-link" aria-describedby="REF31">31</a>].</p>
<p><em>FINErenone in Participants With Type-ONE Diabetes and Chronic Kidney Disease​​</em>​​​​​<em> (Ongoing)</em></p>
<p>Finerenone in Adults with CKD and Type 1 Diabetes phase 3 trial (<a href="https://clinicaltrials.gov/ct2/show/NCT05901831" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05901831</a>) aims to evaluate Finerenone’s effects in 1,650 type 1 diabetes mellitus (T1DM) patients with CKD [<a href="#REF30" class="usa-link" aria-describedby="REF30">30</a>]. Results will determine if Finerenone’s benefits extend beyond T2DM in this high-risk population.</p>
<p>Future directions, potential areas for research, and new opportunities</p>
<p>For the past four decades, most therapies used to treat HF have targeted neurohormonal feedback loops driven by the sympathetic nervous system and the RAAS. These lifesaving and disease-modifying therapies have proven highly effective [<a href="#REF1" class="usa-link" aria-describedby="REF1">1</a>]. However, despite preclinical success, several agents have failed to demonstrate clinical benefit in trials. These failures are multifactorial, attributable not only to high-risk population inclusion, suboptimal therapy implementation, or interpretive challenges [<a href="#REF24" class="usa-link" aria-describedby="REF24">24</a>], but also to trial design limitations (e.g., inadequate statistical power, heterogeneous cohorts, or poorly defined endpoints), drug-specific issues (e.g., pharmacokinetic variability, off-target effects, or insufficient receptor engagement), and unexpectedly low placebo event rates that obscure treatment effects [<a href="#REF1" class="usa-link" aria-describedby="REF1">1</a>,<a href="#REF24" class="usa-link" aria-describedby="REF24">24</a>,<a href="#REF32" class="usa-link" aria-describedby="REF32">32</a>].</p>
<p>Additionally, MRAs may lose efficacy over time due to specific mechanisms such as MR downregulation, aldosterone breakthrough (persistent aldosterone production despite RAAS inhibition), or progressive cardiorenal disease outpacing receptor blockade [<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>,<a href="#REF18" class="usa-link" aria-describedby="REF18">18</a>]. Compensatory activation of alternative pathways (e.g., glucocorticoid receptors) and tissue-specific resistance driven by chronic inflammation or fibrosis further contribute to therapeutic limitations [<a href="#REF18" class="usa-link" aria-describedby="REF18">18</a>,<a href="#REF26" class="usa-link" aria-describedby="REF26">26</a>]. Consequently, there remains a critical need to develop novel MRAs with enhanced potency, selectivity, and safety profiles to address these gaps [<a href="#REF18" class="usa-link" aria-describedby="REF18">18</a>].</p>
<p>Finerenone stands out as a unique nonsteroidal and selective MRA, which has shown improved penetrance into the cardiomyocyte due to its balanced tissue distribution and reduced lipophilicity compared to steroidal MRAs, minimizing off-target accumulation in adipose tissue and kidneys [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>,<a href="#REF10" class="usa-link" aria-describedby="REF10">10</a>]. Its favorable metabolic profile stems from structural modifications that eliminate antiandrogenic and progestogenic activity, thereby avoiding steroidal side effects such as gynecomastia, impotence, or menstrual irregularities [<a href="#REF5" class="usa-link" aria-describedby="REF5">5</a>,<a href="#REF17" class="usa-link" aria-describedby="REF17">17</a>]. Furthermore, Finerenone’s nonsteroidal backbone enhances metabolic stability, reducing risks of drug-drug interactions and improving tolerability in patients with renal impairment [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>,<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>].</p>
<p>Finerenone’s efficacy in reducing cardiorenal risk has been validated in pivotal phase 3 trials (FIDELIO-DKD, FIGARO-DKD) involving patients with T2DM and CKD. Ongoing phase 3 studies, such as FINErenone in participants with type-ONE diabetes and chronic kidney disease (<a href="https://clinicaltrials.gov/ct2/show/NCT05901831" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05901831</a>), aim to extend these findings to type 1 diabetes and nondiabetic CKD populations, ensuring its therapeutic potential is fully explored [<a href="#REF17" class="usa-link" aria-describedby="REF17">17</a>,<a href="#REF30" class="usa-link" aria-describedby="REF30">30</a>].</p>
<p>Emerging interest is growing in combining Finerenone with sodium-glucose cotransporter-2 inhibitors (SGLT2i) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to achieve synergistic cardiorenal protection. Preclinical and clinical evidence suggests complementary mechanisms: Finerenone targets MR-driven inflammation and fibrosis, while SGLT2i and GLP-1 RAs improve hemodynamic load, glycemic control, and tubular function [<a href="#REF33" class="usa-link" aria-describedby="REF33">33</a>]. The COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study trial (<a href="https://clinicaltrials.gov/ct2/show/NCT05254002" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05254002</a>) is evaluating the combined effects of Finerenone and empagliflozin on albuminuria reduction in patients with diabetic kidney disease, demonstrating early promise for dual therapy [<a href="#REF34" class="usa-link" aria-describedby="REF34">34</a>]. Similarly, the Combination Efficacy and Safety Study of Finerenone + SGLT2‑Inhibitor in Hospitalized Heart Failure trial will investigate Finerenone alongside SGLT2i in HF patients, aiming to reduce CV mortality and hospitalization rates [<a href="#REF35" class="usa-link" aria-describedby="REF35">35</a>]. A network meta-analysis by Zhang et al. highlighted that while SGLT2i outperforms Finerenone in reducing renal outcomes and HF hospitalizations, their combination could bridge efficacy gaps, particularly in patients with advanced CKD or residual CV risk [<a href="#REF33" class="usa-link" aria-describedby="REF33">33</a>,<a href="#REF34" class="usa-link" aria-describedby="REF34">34</a>]. Future research should prioritize long-term safety and efficacy data for these combinations, explore optimal dosing regimens, and identify biomarkers to guide personalized therapy.</p>
<p>While trials such as FINEARTS-HF demonstrate Finerenone's potential in reducing HF events and CV death in patients with HFmrEF/HFpEF, longer term real-world data are needed to validate its safety and efficacy beyond controlled trial durations. Specifically, future studies should address hyperkalemia management strategies, renal function decline over extended follow-up periods, and mortality outcomes in broader, unselected populations.</p></section><section id="sec3"><h2 class="pmc_sec_title">Conclusions</h2>
<p>Finerenone’s nonsteroidal structure and selective MR antagonism offer a promising therapeutic alternative with reduced risks of hyperkalemia and endocrine side effects compared to older MRAs. However, its clinical use requires careful monitoring for hyperkalemia and hypotension, particularly in patients with renal impairment or those on concomitant RAAS inhibitors. Robust evidence from pivotal trials-including FIDELIO-DKD, FIGARO-DKD, and FIDELITY-supports Finerenone’s efficacy in reducing renal and CV adverse outcomes in patients with CKD and T2DM. However, broader guideline adoption, cost-effectiveness evaluations, and real-world validation of its long-term benefits and safety will ultimately determine its clinical integration and impact.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Disclosures</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Conflicts of interest:</strong> In compliance with the ICMJE uniform disclosure form, all authors declare the following:</p>
<p><strong>Payment/services info:</strong> All authors have declared that no financial support was received from any organization for the submitted work.</p>
<p><strong>Financial relationships:</strong> All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.</p>
<p><strong>Other relationships:</strong> All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p>
</div></div></section><section id="fn-group2" class="fn-group"><h2 class="pmc_sec_title">Author Contributions</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn2">
<p><strong>Concept and design:</strong>  Mahmoud M. Ramadan, Ousama Mahdi, Shaha Alajmi, Manar Alajmi, Jude Aldouseri , Eva A. Tello, Abdul-Majeed O. Mahdi, Ahmad J. Aladwani, Abdulrahman E. Alayyaf, Mohammed Elmahal </p>
<p><strong>Acquisition, analysis, or interpretation of data:</strong>  Mahmoud M. Ramadan</p>
<p><strong>Drafting of the manuscript:</strong>  Mahmoud M. Ramadan, Ousama Mahdi, Shaha Alajmi, Manar Alajmi, Jude Aldouseri , Eva A. Tello, Abdul-Majeed O. Mahdi, Ahmad J. Aladwani, Abdulrahman E. Alayyaf, Mohammed Elmahal </p>
<p><strong>Critical review of the manuscript for important intellectual content:</strong>  Mahmoud M. Ramadan</p>
<p><strong>Supervision:</strong>  Mahmoud M. Ramadan</p>
</div></div></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="REF1">
<span class="label">1.</span><cite>ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. McMurray JJ, Adamopoulos S, Anker SD, et al.  Eur Heart J. 2012;33:1787–1847. doi: 10.1093/eurheartj/ehs104.</cite> [<a href="https://doi.org/10.1093/eurheartj/ehs104" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22611136/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=ESC%20Guidelines%20for%20the%20diagnosis%20and%20treatment%20of%20acute%20and%20chronic%20heart%20failure%202012:%20the%20Task%20Force%20for%20the%20Diagnosis%20and%20Treatment%20of%20Acute%20and%20Chronic%20Heart%20Failure%202012%20of%20the%20European%20Society%20of%20Cardiology.%20Developed%20in%20collaboration%20with%20the%20Heart%20Failure%20Association%20(HFA)%20of%20the%20ESC&amp;volume=33&amp;publication_year=2012&amp;pages=1787-1847&amp;pmid=22611136&amp;doi=10.1093/eurheartj/ehs104&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF2">
<span class="label">2.</span><cite>Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Dunlay SM, Givertz MM, Aguilar D, et al.  Circulation. 2019;140:0–324. doi: 10.1161/CIR.0000000000000691.</cite> [<a href="https://doi.org/10.1161/CIR.0000000000000691" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31167558/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Type%202%20diabetes%20mellitus%20and%20heart%20failure:%20a%20scientific%20statement%20from%20the%20American%20Heart%20Association%20and%20the%20Heart%20Failure%20Society%20of%20America:%20this%20statement%20does%20not%20represent%20an%20update%20of%20the%202017%20ACC/AHA/HFSA%20heart%20failure%20guideline%20update&amp;volume=140&amp;publication_year=2019&amp;pages=0-324&amp;pmid=31167558&amp;doi=10.1161/CIR.0000000000000691&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF3">
<span class="label">3.</span><cite>Aldosterone in congestive heart failure. Weber KT. N Engl J Med. 2001;345:1689–1697. doi: 10.1056/NEJMra000050.</cite> [<a href="https://doi.org/10.1056/NEJMra000050" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11759649/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Aldosterone%20in%20congestive%20heart%20failure&amp;volume=345&amp;publication_year=2001&amp;pages=1689-1697&amp;pmid=11759649&amp;doi=10.1056/NEJMra000050&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF4">
<span class="label">4.</span><cite>Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Circulation. 1981;63:645–651. doi: 10.1161/01.cir.63.3.645.</cite> [<a href="https://doi.org/10.1161/01.cir.63.3.645" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7006851/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Relation%20of%20the%20renin-angiotensin-aldosterone%20system%20to%20clinical%20state%20in%20congestive%20heart%20failure&amp;volume=63&amp;publication_year=1981&amp;pages=645-651&amp;pmid=7006851&amp;doi=10.1161/01.cir.63.3.645&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF5">
<span class="label">5.</span><cite>Eplerenone in patients with systolic heart failure and mild symptoms. Zannad F, McMurray JJ, Krum H, et al.  N Engl J Med. 2011;364:11–21. doi: 10.1056/NEJMoa1009492.</cite> [<a href="https://doi.org/10.1056/NEJMoa1009492" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21073363/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Eplerenone%20in%20patients%20with%20systolic%20heart%20failure%20and%20mild%20symptoms&amp;volume=364&amp;publication_year=2011&amp;pages=11-21&amp;pmid=21073363&amp;doi=10.1056/NEJMoa1009492&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF6">
<span class="label">6.</span><cite>The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Pitt B, Zannad F, Remme WJ, et al.  N Engl J Med. 1999;341:709–717. doi: 10.1056/NEJM199909023411001.</cite> [<a href="https://doi.org/10.1056/NEJM199909023411001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10471456/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=The%20effect%20of%20spironolactone%20on%20morbidity%20and%20mortality%20in%20patients%20with%20severe%20heart%20failure&amp;volume=341&amp;publication_year=1999&amp;pages=709-717&amp;pmid=10471456&amp;doi=10.1056/NEJM199909023411001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF7">
<span class="label">7.</span><cite>Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Weir MR, Rolfe M. Clin J Am Soc Nephrol. 2010;5:531–548. doi: 10.2215/CJN.07821109.</cite> [<a href="https://doi.org/10.2215/CJN.07821109" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20150448/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20J%20Am%20Soc%20Nephrol&amp;title=Potassium%20homeostasis%20and%20renin-angiotensin-aldosterone%20system%20inhibitors&amp;volume=5&amp;publication_year=2010&amp;pages=531-548&amp;pmid=20150448&amp;doi=10.2215/CJN.07821109&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF8">
<span class="label">8.</span><cite>Finerenone: a novel drug discovery for the treatment of chronic kidney disease. Rana A, Sahu JK. Curr Drug Discov Technol. 2024;21:0. doi: 10.2174/0115701638283354240103115420.</cite> [<a href="https://doi.org/10.2174/0115701638283354240103115420" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38288821/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Drug%20Discov%20Technol&amp;title=Finerenone:%20a%20novel%20drug%20discovery%20for%20the%20treatment%20of%20chronic%20kidney%20disease&amp;volume=21&amp;publication_year=2024&amp;pages=0&amp;pmid=38288821&amp;doi=10.2174/0115701638283354240103115420&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF9">
<span class="label">9.</span><cite>Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. Kolkhof P, Delbeck M, Kretschmer A, et al.  J Cardiovasc Pharmacol. 2014;64:69–78. doi: 10.1097/FJC.0000000000000091.</cite> [<a href="https://doi.org/10.1097/FJC.0000000000000091" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24621652/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Cardiovasc%20Pharmacol&amp;title=Finerenone,%20a%20novel%20selective%20nonsteroidal%20mineralocorticoid%20receptor%20antagonist%20protects%20from%20rat%20cardiorenal%20injury&amp;volume=64&amp;publication_year=2014&amp;pages=69-78&amp;pmid=24621652&amp;doi=10.1097/FJC.0000000000000091&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF10">
<span class="label">10.</span><cite>Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. Bakris GL, Agarwal R, Chan JC, et al.  JAMA. 2015;314:884–894. doi: 10.1001/jama.2015.10081.</cite> [<a href="https://doi.org/10.1001/jama.2015.10081" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26325557/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Effect%20of%20finerenone%20on%20albuminuria%20in%20patients%20with%20diabetic%20nephropathy:%20a%20randomized%20clinical%20trial&amp;volume=314&amp;publication_year=2015&amp;pages=884-894&amp;pmid=26325557&amp;doi=10.1001/jama.2015.10081&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF11">
<span class="label">11.</span><cite>Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. Bakris GL, Agarwal R, Anker SD, et al.  N Engl J Med. 2020;383:2219–2229. doi: 10.1056/NEJMoa2025845.</cite> [<a href="https://doi.org/10.1056/NEJMoa2025845" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33264825/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Effect%20of%20finerenone%20on%20chronic%20kidney%20disease%20outcomes%20in%20type%202%20diabetes&amp;volume=383&amp;publication_year=2020&amp;pages=2219-2229&amp;pmid=33264825&amp;doi=10.1056/NEJMoa2025845&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF12">
<span class="label">12.</span><cite>Cardiovascular events with finerenone in kidney disease and type 2 diabetes. Pitt B, Filippatos G, Agarwal R, et al.  N Engl J Med. 2021;385:2252–2263. doi: 10.1056/NEJMoa2110956.</cite> [<a href="https://doi.org/10.1056/NEJMoa2110956" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34449181/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Cardiovascular%20events%20with%20finerenone%20in%20kidney%20disease%20and%20type%202%20diabetes&amp;volume=385&amp;publication_year=2021&amp;pages=2252-2263&amp;pmid=34449181&amp;doi=10.1056/NEJMoa2110956&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF13">
<span class="label">13.</span><cite>Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Weber KT, Brilla CG. Circulation. 1991;83:1849–1865. doi: 10.1161/01.cir.83.6.1849.</cite> [<a href="https://doi.org/10.1161/01.cir.83.6.1849" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1828192/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Pathological%20hypertrophy%20and%20cardiac%20interstitium.%20Fibrosis%20and%20renin-angiotensin-aldosterone%20system&amp;volume=83&amp;publication_year=1991&amp;pages=1849-1865&amp;pmid=1828192&amp;doi=10.1161/01.cir.83.6.1849&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF14">
<span class="label">14.</span><cite>Aldosterone and the heart. Young M, Funder JW. Trends Endocrinol Metab. 2000;11:224–226. doi: 10.1016/s1043-2760(00)00270-8.</cite> [<a href="https://doi.org/10.1016/s1043-2760(00)00270-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10878752/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Trends%20Endocrinol%20Metab&amp;title=Aldosterone%20and%20the%20heart&amp;volume=11&amp;publication_year=2000&amp;pages=224-226&amp;pmid=10878752&amp;doi=10.1016/s1043-2760(00)00270-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF15">
<span class="label">15.</span><cite>Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. Pitt B, Remme W, Zannad F, et al.  N Engl J Med. 2003;348:1309–1321. doi: 10.1056/NEJMoa030207.</cite> [<a href="https://doi.org/10.1056/NEJMoa030207" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12668699/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Eplerenone,%20a%20selective%20aldosterone%20blocker,%20in%20patients%20with%20left%20ventricular%20dysfunction%20after%20myocardial%20infarction&amp;volume=348&amp;publication_year=2003&amp;pages=1309-1321&amp;pmid=12668699&amp;doi=10.1056/NEJMoa030207&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF16">
<span class="label">16.</span><cite>Corticosteroid receptors, macrophages and cardiovascular disease. Rickard AJ, Young MJ. J Mol Endocrinol. 2009;42:449–459. doi: 10.1677/JME-08-0144.</cite> [<a href="https://doi.org/10.1677/JME-08-0144" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19158233/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Mol%20Endocrinol&amp;title=Corticosteroid%20receptors,%20macrophages%20and%20cardiovascular%20disease&amp;volume=42&amp;publication_year=2009&amp;pages=449-459&amp;pmid=19158233&amp;doi=10.1677/JME-08-0144&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF17">
<span class="label">17.</span><cite>Rationale and design of mineralocorticoid receptor antagonist tolerability study-heart failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Pitt B, Anker SD, Böhm M, et al.  Eur J Heart Fail. 2015;17:224–232. doi: 10.1002/ejhf.218.</cite> [<a href="https://doi.org/10.1002/ejhf.218" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25678098/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Heart%20Fail&amp;title=Rationale%20and%20design%20of%20mineralocorticoid%20receptor%20antagonist%20tolerability%20study-heart%20failure%20(ARTS-HF):%20a%20randomized%20study%20of%20finerenone%20vs.%20eplerenone%20in%20patients%20who%20have%20worsening%20chronic%20heart%20failure%20with%20diabetes%20and/or%20chronic%20kidney%20disease&amp;volume=17&amp;publication_year=2015&amp;pages=224-232&amp;pmid=25678098&amp;doi=10.1002/ejhf.218&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF18">
<span class="label">18.</span><cite>30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development. Kolkhof P, Bärfacker L. J Endocrinol. 2017;234:0–40. doi: 10.1530/JOE-16-0600.</cite> [<a href="https://doi.org/10.1530/JOE-16-0600" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5488394/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28634268/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Endocrinol&amp;title=30%20years%20of%20the%20mineralocorticoid%20receptor:%20mineralocorticoid%20receptor%20antagonists:%2060%20years%20of%20research%20and%20development&amp;volume=234&amp;publication_year=2017&amp;pages=0-40&amp;pmid=28634268&amp;doi=10.1530/JOE-16-0600&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF19">
<span class="label">19.</span><cite>A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Filippatos G, Anker SD, Böhm M, et al.  Eur Heart J. 2016;37:2105–2114. doi: 10.1093/eurheartj/ehw132.</cite> [<a href="https://doi.org/10.1093/eurheartj/ehw132" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4946749/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27130705/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=A%20randomized%20controlled%20study%20of%20finerenone%20vs.%20eplerenone%20in%20patients%20with%20worsening%20chronic%20heart%20failure%20and%20diabetes%20mellitus%20and/or%20chronic%20kidney%20disease&amp;volume=37&amp;publication_year=2016&amp;pages=2105-2114&amp;pmid=27130705&amp;doi=10.1093/eurheartj/ehw132&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF20">
<span class="label">20.</span><cite>Finerenone for patients with CKD and type 2 diabetes. Slomski A. JAMA. 2021;325:713. doi: 10.1001/jama.2021.1255.</cite> [<a href="https://doi.org/10.1001/jama.2021.1255" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33620401/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Finerenone%20for%20patients%20with%20CKD%20and%20type%202%20diabetes&amp;volume=325&amp;publication_year=2021&amp;pages=713&amp;pmid=33620401&amp;doi=10.1001/jama.2021.1255&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF21">
<span class="label">21.</span><cite>Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis. Rossing P, Anker SD, Filippatos G, et al.  Diabetes Care. 2022;45:2991–2998. doi: 10.2337/dc22-0294.</cite> [<a href="https://doi.org/10.2337/dc22-0294" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9862372/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35972218/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&amp;title=Finerenone%20in%20patients%20with%20chronic%20kidney%20disease%20and%20type%202%20diabetes%20by%20sodium-glucose%20cotransporter%202%20inhibitor%20treatment:%20the%20FIDELITY%20analysis&amp;volume=45&amp;publication_year=2022&amp;pages=2991-2998&amp;pmid=35972218&amp;doi=10.2337/dc22-0294&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF22">
<span class="label">22.</span><cite>The role of aldosterone and mineralocorticoid receptors in cardiovascular disease. Funder JW. Am J Cardiovasc Drugs. 2007;7:151–157. doi: 10.2165/00129784-200707030-00001.</cite> [<a href="https://doi.org/10.2165/00129784-200707030-00001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17610342/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Cardiovasc%20Drugs&amp;title=The%20role%20of%20aldosterone%20and%20mineralocorticoid%20receptors%20in%20cardiovascular%20disease&amp;volume=7&amp;publication_year=2007&amp;pages=151-157&amp;pmid=17610342&amp;doi=10.2165/00129784-200707030-00001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF23">
<span class="label">23.</span><cite>Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Circulation. 1990;82:1730–1736. doi: 10.1161/01.cir.82.5.1730.</cite> [<a href="https://doi.org/10.1161/01.cir.82.5.1730" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2225374/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Hormones%20regulating%20cardiovascular%20function%20in%20patients%20with%20severe%20congestive%20heart%20failure%20and%20their%20relation%20to%20mortality.%20CONSENSUS%20Trial%20Study%20Group&amp;volume=82&amp;publication_year=1990&amp;pages=1730-1736&amp;pmid=2225374&amp;doi=10.1161/01.cir.82.5.1730&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF24">
<span class="label">24.</span><cite>How should we sequence the treatments for heart failure and a reduced ejection fraction?: A redefinition of evidence-based medicine. McMurray JJ, Packer M. Circulation. 2021;143:875–877. doi: 10.1161/CIRCULATIONAHA.120.052926.</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.120.052926" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33378214/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=How%20should%20we%20sequence%20the%20treatments%20for%20heart%20failure%20and%20a%20reduced%20ejection%20fraction?:%20A%20redefinition%20of%20evidence-based%20medicine&amp;volume=143&amp;publication_year=2021&amp;pages=875-877&amp;pmid=33378214&amp;doi=10.1161/CIRCULATIONAHA.120.052926&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF25">
<span class="label">25.</span><cite>Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Pitt B, Kober L, Ponikowski P, et al.  Eur Heart J. 2013;34:2453–2463. doi: 10.1093/eurheartj/eht187.</cite> [<a href="https://doi.org/10.1093/eurheartj/eht187" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3743070/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23713082/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=Safety%20and%20tolerability%20of%20the%20novel%20non-steroidal%20mineralocorticoid%20receptor%20antagonist%20BAY%2094-8862%20in%20patients%20with%20chronic%20heart%20failure%20and%20mild%20or%20moderate%20chronic%20kidney%20disease:%20a%20randomized,%20double-blind%20trial&amp;volume=34&amp;publication_year=2013&amp;pages=2453-2463&amp;pmid=23713082&amp;doi=10.1093/eurheartj/eht187&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF26">
<span class="label">26.</span><cite>Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. Kolkhof P, Jaisser F, Kim SY, Filippatos G, Nowack C, Pitt B. Handb Exp Pharmacol. 2017;243:271–305. doi: 10.1007/164_2016_76.</cite> [<a href="https://doi.org/10.1007/164_2016_76" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27830348/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Handb%20Exp%20Pharmacol&amp;title=Steroidal%20and%20novel%20non-steroidal%20mineralocorticoid%20receptor%20antagonists%20in%20heart%20failure%20and%20cardiorenal%20diseases:%20comparison%20at%20bench%20and%20bedside&amp;volume=243&amp;publication_year=2017&amp;pages=271-305&amp;pmid=27830348&amp;doi=10.1007/164_2016_76&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF27">
<span class="label">27.</span><cite>Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: rationale and design of the FINEARTS-HF trial. Vaduganathan M, Claggett BL, Lam CS, et al.  Eur J Heart Fail. 2024;26:1324–1333. doi: 10.1002/ejhf.3253.</cite> [<a href="https://doi.org/10.1002/ejhf.3253" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38742248/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Heart%20Fail&amp;title=Finerenone%20in%20patients%20with%20heart%20failure%20with%20mildly%20reduced%20or%20preserved%20ejection%20fraction:%20rationale%20and%20design%20of%20the%20FINEARTS-HF%20trial&amp;volume=26&amp;publication_year=2024&amp;pages=1324-1333&amp;pmid=38742248&amp;doi=10.1002/ejhf.3253&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF28">
<span class="label">28.</span><cite>Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Ruilope LM, Agarwal R, Chan JC, et al.  Am J Nephrol. 2014;40:572–581. doi: 10.1159/000371497.</cite> [<a href="https://doi.org/10.1159/000371497" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25591469/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Nephrol&amp;title=Rationale,%20design,%20and%20baseline%20characteristics%20of%20ARTS-DN:%20a%20randomized%20study%20to%20assess%20the%20safety%20and%20efficacy%20of%20finerenone%20in%20patients%20with%20type%202%20diabetes%20mellitus%20and%20a%20clinical%20diagnosis%20of%20diabetic%20nephropathy&amp;volume=40&amp;publication_year=2014&amp;pages=572-581&amp;pmid=25591469&amp;doi=10.1159/000371497&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF29">
<span class="label">29.</span><cite>Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Agarwal R, Filippatos G, Pitt B, et al.  Eur Heart J. 2022;10:474–484. doi: 10.1093/eurheartj/ehab777.</cite> [<a href="https://doi.org/10.1093/eurheartj/ehab777" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8830527/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35023547/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=Cardiovascular%20and%20kidney%20outcomes%20with%20finerenone%20in%20patients%20with%20type%202%20diabetes%20and%20chronic%20kidney%20disease:%20the%20FIDELITY%20pooled%20analysis&amp;volume=10&amp;publication_year=2022&amp;pages=474-484&amp;pmid=35023547&amp;doi=10.1093/eurheartj/ehab777&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF30">
<span class="label">30.</span><cite>National Library of Medicine (U.S.). (2023. Finerenone in adults with chronic kidney disease and type 1 diabetes (FINE-ONE)  [
Jun;
2025 
]. 2023. <a href="https://clinicaltrials.gov/study/NCT05901831" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://clinicaltrials.gov/study/NCT05901831</a> <a href="https://clinicaltrials.gov/study/NCT05901831" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://clinicaltrials.gov/study/NCT05901831</a></cite>
</li>
<li id="REF31">
<span class="label">31.</span><cite>Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. Palmer BF. N Engl J Med. 2004;351:585–592. doi: 10.1056/NEJMra035279.</cite> [<a href="https://doi.org/10.1056/NEJMra035279" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15295051/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Managing%20hyperkalemia%20caused%20by%20inhibitors%20of%20the%20renin-angiotensin-aldosterone%20system&amp;volume=351&amp;publication_year=2004&amp;pages=585-592&amp;pmid=15295051&amp;doi=10.1056/NEJMra035279&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF32">
<span class="label">32.</span><cite>Effects of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, on cardiovascular disease, chronic kidney disease, and blood pressure. Ravid JD, Laffin LJ. Curr Cardiol Rep. 2022;24:1251–1259. doi: 10.1007/s11886-022-01750-0.</cite> [<a href="https://doi.org/10.1007/s11886-022-01750-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35925515/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Cardiol%20Rep&amp;title=Effects%20of%20finerenone,%20a%20novel%20nonsteroidal%20mineralocorticoid%20receptor%20antagonist,%20on%20cardiovascular%20disease,%20chronic%20kidney%20disease,%20and%20blood%20pressure&amp;volume=24&amp;publication_year=2022&amp;pages=1251-1259&amp;pmid=35925515&amp;doi=10.1007/s11886-022-01750-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF33">
<span class="label">33.</span><cite>Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. Zhang Y, Jiang L, Wang J, et al.  Cardiovasc Diabetol. 2022;21:232. doi: 10.1186/s12933-022-01676-5.</cite> [<a href="https://doi.org/10.1186/s12933-022-01676-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9637313/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36335326/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cardiovasc%20Diabetol&amp;title=Network%20meta-analysis%20on%20the%20effects%20of%20finerenone%20versus%20SGLT2%20inhibitors%20and%20GLP-1%20receptor%20agonists%20on%20cardiovascular%20and%20renal%20outcomes%20in%20patients%20with%20type%202%20diabetes%20mellitus%20and%20chronic%20kidney%20disease&amp;volume=21&amp;publication_year=2022&amp;pages=232&amp;pmid=36335326&amp;doi=10.1186/s12933-022-01676-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF34">
<span class="label">34.</span><cite>Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE) Green JB, Mottl AK, Bakris G, et al.  Nephrol Dial Transplant. 2023;38:894–903. doi: 10.1093/ndt/gfac198.</cite> [<a href="https://doi.org/10.1093/ndt/gfac198" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10064838/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35700142/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nephrol%20Dial%20Transplant&amp;title=Design%20of%20the%20COmbinatioN%20effect%20of%20FInerenone%20anD%20EmpaglifloziN%20in%20participants%20with%20chronic%20kidney%20disease%20and%20type%202%20diabetes%20using%20a%20UACR%20Endpoint%20study%20(CONFIDENCE)&amp;volume=38&amp;publication_year=2023&amp;pages=894-903&amp;pmid=35700142&amp;doi=10.1093/ndt/gfac198&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF35">
<span class="label">35.</span><cite>A study to determine the efficacy and safety of finerenone and SGLT2i in combination in hospitalized patients with heart failure (CONFIRMATION-HF) (CONFIRMATION) Updated 22 July.  [
Aug;
2024 
]. 2024. <a href="https://clinicaltrials.gov/ct2/show/NCT06024746" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://clinicaltrials.gov/ct2/show/NCT06024746</a> <a href="https://clinicaltrials.gov/ct2/show/NCT06024746" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://clinicaltrials.gov/ct2/show/NCT06024746</a></cite>
</li>
</ul></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Cureus are provided here courtesy of <strong>Cureus Inc.</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.7759/cureus.87706"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/cureus-0017-00000087706.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (206.3 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12335729/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12335729/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12335729%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335729/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12335729/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12335729/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40786373/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12335729/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40786373/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12335729/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12335729/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="2H7Dp5WbD17n12zKDgg9uok9U6AhEFR3JHHp92xIEJWp6k6tsY59yD0gNZiN5iXW">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-370d5dd6.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-917ba005.js"></script>
    
    

    </body>
</html>
